<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633152</url>
  </required_header>
  <id_info>
    <org_study_id>P903-19</org_study_id>
    <nct_id>NCT00633152</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Intramuscular Ceftaroline Versus Intravenous Linezolid in Adult Subjects With Complicated Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ceftaroline is effective and safe in the
      treatment of complicated skin and skin structure infections in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether ceftaroline is effective and safe in the
      treatment of complicated skin and skin structure infections in adults. The primary focus is
      bacterial infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response at the Test of Cure (TOC) Visit in the Modified Intent-to-treat (MITT) Population</measure>
    <time_frame>Test of Cure Visit (8 to 15 days after end of therapy)</time_frame>
    <description>The coprimary efficacy outcome measures were the per-subject clinical cure rate at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) and (Modified-Intent-to-Treat) MITT Populations. Subjects were considered clinically cured at the Test of Cure (TOC) Visit if they had total resolution of all signs and symptoms of the baseline infection, or improvement of the infection to such an extent that no further antimicrobial therapy was necessary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population</measure>
    <time_frame>Test of Cure Visit (8 to 15 Days after end of therapy)</time_frame>
    <description>The coprimary efficacy outcome measures were the per-subject clinical cure rate at the TOC Visit in the CE and MITT Populations. Subjects were considered clinically cured at the TOC Visit if they had total resolution of all signs and symptoms of the baseline infection, or improvement of the infection to such an extent that no further antimicrobial therapy was necessary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure Rate at the TOC Visit in the cMITT Population</measure>
    <time_frame>TOC Visit (8 to 15 days after end of therapy)</time_frame>
    <description>Evaluate per-subject the clinical response at the Test-of-Cure (TOC) Visit in the Clinical Modified Intent-to-treat (cMITT) Population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response at the End-of-Therapy (EOT) Visit in the MITT, cMITT and CE Populations.</measure>
    <time_frame>End-of-therapy (EOT) visit</time_frame>
    <description>Evaluate per-subject the clinical response at the End-of-therapy (EOT) Visit in the MITT, cMITT and CE populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Microbiological Response at the TOC Visit in the mMITT and ME Populations.</measure>
    <time_frame>TOC Visit (8 to 15 days after end of therapy)</time_frame>
    <description>Evaluate per-subject the microbiological response at the TOC Visit in the Microbiological Modified Intent-to-treat (mMITT) and Microbiologically Evaluable (ME) populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and Microbiological Response by Pathogen at the TOC Visit in the mMITT and ME Populations</measure>
    <time_frame>TOC Visit (8 to 15 days after end of therapy)</time_frame>
    <description>Evaluate the clinical and microbiological response by pathogen at the TOC Visit in the mMITT and ME populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relapse at the Late Follow-up Visit</measure>
    <time_frame>Late Follow-up (LFU) Visit (21 to 35 days after end of therapy)</time_frame>
    <description>Evaluate Clinical relapse rate at Late Follow-up (LFU) (21 to 45 days after the final dose of study drug)in those subjects clinically cured at the TOC visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Microbiological Reinfection or Recurrence at the Late Follow-up (LFU) Visit</measure>
    <time_frame>LFU Visit (21 to 35 days after end of therapy)</time_frame>
    <description>Evaluate per-subject reinfection or recurrence rate at the LFU Visit in those subjects who had a favorable microbiological outcome (eradication or presumed eradication) at the TOC Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Safety of Ceftaroline Fosamil</measure>
    <time_frame>First dose of study drug through LFU Visit or 30 days after the last dose of study drug</time_frame>
    <description>Evaluate safety of Ceftaroline fosamil IM in adults with complicated skin and skin structure infection (cSSSI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Bacterial Infection</condition>
  <arm_group>
    <arm_group_label>Ceftaroline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linezolid plus optional aztreonam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftaroline</intervention_name>
    <description>600 mg injected every 12 hours for at least 5 but not more than 14 days</description>
    <arm_group_label>Ceftaroline</arm_group_label>
    <other_name>ceftaroline fosamil</other_name>
    <other_name>ceftaroline for injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid</intervention_name>
    <description>600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days</description>
    <arm_group_label>linezolid plus optional aztreonam</arm_group_label>
    <other_name>Zyvox</other_name>
    <other_name>Zyvoxid</other_name>
    <other_name>CAS number 165800-03-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aztreonam</intervention_name>
    <description>1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.</description>
    <arm_group_label>linezolid plus optional aztreonam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Complicated skin and skin structure infection (cSSSI)

          -  Require initial hospitalization, or treatment in an emergency room or urgent care
             setting

        Exclusion Criteria:

          -  Hypersensitivity or allergic reaction to any ÃŸ-lactam, ceftaroline, linezolid,
             aztreonam, or to their components

          -  Concomitant use of adrenergic or serotonergic agent

          -  Uncomplicated skin and skin structure infection

          -  Concomitant therapy with any drug known to exhibit a contraindicated drug-drug
             interaction

          -  More than 24 hours of treatment with an antimicrobial within 96 hours before
             randomization

          -  Known or suspected endocarditis, osteomyelitis, or septic arthritis

          -  Severely impaired renal function

          -  Evidence of significant hepatic, hematologic, or immunologic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor Cerexa</last_name>
    <role>Study Director</role>
    <affiliation>Forest Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>96020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Rolling Hills Estate</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2008</study_first_posted>
  <results_first_submitted>July 25, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>complicated skin and skin structure infections</keyword>
  <keyword>linezolid</keyword>
  <keyword>ceftaroline</keyword>
  <keyword>clinical response</keyword>
  <keyword>microbiological response</keyword>
  <keyword>Cellulitis</keyword>
  <keyword>Abscess</keyword>
  <keyword>Wound infection</keyword>
  <keyword>Deeper soft tissue</keyword>
  <keyword>Significant surgical intervention</keyword>
  <keyword>Gram-positive bacterial infection</keyword>
  <keyword>Gram-negative bacterial infection</keyword>
  <keyword>bacterial infection</keyword>
  <keyword>cephalosporin</keyword>
  <keyword>broad-spectrum activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twelve (12) study centers in the U.S. participated in this open label trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ceftaroline</title>
          <description>Intramuscular every 12 hours</description>
        </group>
        <group group_id="P2">
          <title>Linezolid</title>
          <description>Intravenous Linezolid every 12 hours (with or without Aztreonam)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>MITT and Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Clinically Evaluable Population</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ceftaroline</title>
          <description>Intramuscular every 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Linezolid</title>
          <description>Intravenous Linezolid every 12 hours (with or without Aztreonam)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="12.83"/>
                    <measurement group_id="B2" value="39.9" spread="14.58"/>
                    <measurement group_id="B3" value="39.7" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response at the Test of Cure (TOC) Visit in the Modified Intent-to-treat (MITT) Population</title>
        <description>The coprimary efficacy outcome measures were the per-subject clinical cure rate at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) and (Modified-Intent-to-Treat) MITT Populations. Subjects were considered clinically cured at the Test of Cure (TOC) Visit if they had total resolution of all signs and symptoms of the baseline infection, or improvement of the infection to such an extent that no further antimicrobial therapy was necessary.</description>
        <time_frame>Test of Cure Visit (8 to 15 days after end of therapy)</time_frame>
        <population>Modified-Intent-to-Treat (MITT) Population - Any randomized subjects that received any amount of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftaroline</title>
            <description>Ceftaroline was administered 600 mg as an Intramuscular injection every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Linezolid (With or Without Aztreonam)</title>
            <description>Linezolid was administered as 600 mg Intravenous infusions over 60 minutes every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response at the Test of Cure (TOC) Visit in the Modified Intent-to-treat (MITT) Population</title>
          <description>The coprimary efficacy outcome measures were the per-subject clinical cure rate at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) and (Modified-Intent-to-Treat) MITT Populations. Subjects were considered clinically cured at the Test of Cure (TOC) Visit if they had total resolution of all signs and symptoms of the baseline infection, or improvement of the infection to such an extent that no further antimicrobial therapy was necessary.</description>
          <population>Modified-Intent-to-Treat (MITT) Population - Any randomized subjects that received any amount of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="76.0" upper_limit="91.2"/>
                    <measurement group_id="O2" value="88.9" lower_limit="75.9" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population</title>
        <description>The coprimary efficacy outcome measures were the per-subject clinical cure rate at the TOC Visit in the CE and MITT Populations. Subjects were considered clinically cured at the TOC Visit if they had total resolution of all signs and symptoms of the baseline infection, or improvement of the infection to such an extent that no further antimicrobial therapy was necessary.</description>
        <time_frame>Test of Cure Visit (8 to 15 Days after end of therapy)</time_frame>
        <population>The Clinically Evaluable (CE) Population included all subjects who satisfied key minimum protocol criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftaroline</title>
            <description>Ceftaroline fosamil was administered 600mg IM every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Linezolid (With or Without Aztreonam)</title>
            <description>Linezolid was administered as 600 mg IV infusions over 60 minutes q12h</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population</title>
          <description>The coprimary efficacy outcome measures were the per-subject clinical cure rate at the TOC Visit in the CE and MITT Populations. Subjects were considered clinically cured at the TOC Visit if they had total resolution of all signs and symptoms of the baseline infection, or improvement of the infection to such an extent that no further antimicrobial therapy was necessary.</description>
          <population>The Clinically Evaluable (CE) Population included all subjects who satisfied key minimum protocol criteria</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="82.5" upper_limit="95.9"/>
                    <measurement group_id="O2" value="97.4" lower_limit="86.5" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure Rate at the TOC Visit in the cMITT Population</title>
        <description>Evaluate per-subject the clinical response at the Test-of-Cure (TOC) Visit in the Clinical Modified Intent-to-treat (cMITT) Population.</description>
        <time_frame>TOC Visit (8 to 15 days after end of therapy)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response at the End-of-Therapy (EOT) Visit in the MITT, cMITT and CE Populations.</title>
        <description>Evaluate per-subject the clinical response at the End-of-therapy (EOT) Visit in the MITT, cMITT and CE populations.</description>
        <time_frame>End-of-therapy (EOT) visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Microbiological Response at the TOC Visit in the mMITT and ME Populations.</title>
        <description>Evaluate per-subject the microbiological response at the TOC Visit in the Microbiological Modified Intent-to-treat (mMITT) and Microbiologically Evaluable (ME) populations.</description>
        <time_frame>TOC Visit (8 to 15 days after end of therapy)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical and Microbiological Response by Pathogen at the TOC Visit in the mMITT and ME Populations</title>
        <description>Evaluate the clinical and microbiological response by pathogen at the TOC Visit in the mMITT and ME populations.</description>
        <time_frame>TOC Visit (8 to 15 days after end of therapy)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relapse at the Late Follow-up Visit</title>
        <description>Evaluate Clinical relapse rate at Late Follow-up (LFU) (21 to 45 days after the final dose of study drug)in those subjects clinically cured at the TOC visit.</description>
        <time_frame>Late Follow-up (LFU) Visit (21 to 35 days after end of therapy)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Microbiological Reinfection or Recurrence at the Late Follow-up (LFU) Visit</title>
        <description>Evaluate per-subject reinfection or recurrence rate at the LFU Visit in those subjects who had a favorable microbiological outcome (eradication or presumed eradication) at the TOC Visit.</description>
        <time_frame>LFU Visit (21 to 35 days after end of therapy)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Safety of Ceftaroline Fosamil</title>
        <description>Evaluate safety of Ceftaroline fosamil IM in adults with complicated skin and skin structure infection (cSSSI)</description>
        <time_frame>First dose of study drug through LFU Visit or 30 days after the last dose of study drug</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date of First Dose of study drug to the TOC visit (AEs) or LFU visit (SAEs).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ceftaroline</title>
          <description>Intramuscular every 12 hours</description>
        </group>
        <group group_id="E2">
          <title>Linezolid</title>
          <description>Intravenous Linezolid every 12 hours (with or without Aztreonam)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Necrotizing fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <description>Administration site conditions</description>
                <counts group_id="E1" events="60" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Clinical Sciences</name_or_title>
      <organization>Cerexa, Inc.</organization>
      <phone>510-285-9200</phone>
      <email>clinicaltrials@cerexa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

